Nirogacestat
- Generic Name
- Nirogacestat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H41F2N5O
- CAS Number
- 1290543-63-3
- Unique Ingredient Identifier
- QZ62892OFJ
- Background
Nirogacestat has been used in trials studying the treatment of Breast Cancer, HIV Infection, Desmoid Tumors, Advanced Solid Tumors, and Aggressive Fibromatosis, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 464
- Registration Number
- NCT04126200
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Allogene Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT04093596
- Locations
- 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath